Home
Pipeline
ColiFinĀ®
Inhaled Murepavadin
Balixafortide
Lonodelestat (external)
Breakthrough Platforms
Partnering
About us
Investor Relations
Corporate Governance*
Reporting*
Corporate Presentation
Share Information
Media Releases
Ad-hoc Releases
Calendar
Contact
Careers
Contact
News on home
Spexis
>
News on home
Latest news
Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024.Ā
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
See all news
This site uses cookies:
Find out more.
Accept